drugset / Trial / NCT04535960

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

NCT04535960

Phase 2 Unknown 36 enrolled University Health Network, Toronto
RandomizedSequentialOpen-labelTreatment

Summary

This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients. Ultimately, by obtaining physiological data in T2D patients without HF, our aims are to gain insight into how the use of this combined therapy may be used in T2D with HF in future work.

Timeline

Start
2019-01-24
Primary completion
2023-10
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral
Subject Liraglutide Peptide 1.8 mg Subcutaneous